$BLSM

BlossomHill Therapeutics (BLSM) and Foundation Medicine are collaborating to develop a companion diagnostic assay for the EGFR C797S resistance mutation in non-small cell lung cancer (NSCLC). The assay will support the ongoing Phase 1/2 SOLARA trial of BH-30643, a novel EGFR inhibitor designed to overcome resistance to existing treatments. BH-30643 has received Fast Track designation and is being evaluated in over 40 sites across 10 countries.

Amneal Pharmaceuticals (AMRX) rose 7% to $21.17 after FDA approval for a generic Lanreotide injection. BlossomHill Therapeutics (BLSM) climbed 6% to $27.99 following positive Phase 1/2 study results. Neogen (NEOG) increased 2% to $13.34 after reporting Q4 revenue of $225M. NeoGenomics (NEO) hit a 52-week high of $20.05 after announcing Medicare and Medicaid coverage for its RaDaR ST test.

BlossomHill Therapeutics (BLSM) reported a wider Q2 2026 loss of $23.8M, with R&D expenses rising to $21.4M. The FDA granted Fast Track designation to BH-30643 for NSCLC treatment. The company expects to fund operations into Q2 2028 following a $168.3M IPO. BH-30643 showed 45% response rate in trials.

BlossomHill Therapeutics reported a net loss of $23.8M for Q3 2026, widening from a $13.2M loss a year ago, with no revenue as it remains in clinical stages. The company is progressing with multiple clinical trials and expects IPO proceeds to fund operations into Q2 2028.

BlossomHill Therapeutics, Inc. (BLSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-p

BlossomHill Therapeutics (BLSM) reported Q2 2026 results, including $168.3M from IPO, $95.4M in cash, and FDA Fast Track designation for BH-30643. The drug showed 45% response rate in lung cancer trials. R&D expenses rose to $21.4M, leading to a $23.8M net loss. The company expects funding into Q2 2028.

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

BlossomHill Therapeutics (BLSM) presented Phase 1/2 trial data showing its drug BH-30643 achieved a 45% response rate in EGFR C797S-positive NSCLC patients. The stock rose 6% following the announcement. The drug has FDA Fast Track designation, and experts note its potential for addressing treatment-resistant mutations.

BlossomHill Therapeutics (BLSM) stock rose 4.4% in pre-market trading after presenting positive Phase 1/2 trial data for BH-30643 at a lung cancer conference. The drug showed a 45% response rate in treatment-resistant patients. CEO J. Jean Cui also presented at an investment conference, and Guggenheim initiated coverage with a Buy rating and $30 price target. The stock is near its 52-week high of $23.37.

BlossomHill Therapeutics, Inc. (BLSM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR ™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer 45% objective response rate a